Mobile

A randomized, 24-week, double-blind, placebo-controlled, parallel-group, multicenter study to assess the efficacy and safety of Omalizumab in adult patients with chronic urticaria who exhibit IgE agai...

Update Il y a 4 ans
Reference: EUCTR2006-005404-13

A randomized, 24-week, double-blind, placebo-controlled, parallel-group, multicenter study to assess the efficacy and safety of Omalizumab in adult patients with chronic urticaria who exhibit IgE against thyreoperoxidase

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To demonstrate that omalizumab, compared to omalizumab-Placebo, has superior efficacy as for urticaria activity score (UAS7) after 24 weeks of treatment in adult patients with moderate to severe chronic urticaria who exhibit IgE against thyreoperoxidase.

Inclusion criteria

  • Chronic urticaria

Links